Protease-activated receptor-1 antagonists: Focus on SCH 530348

American Journal of Therapeutics

Volumn 19, Issue 6, 2012, Pages 465-469

  Sugunaraj, Jaya Prakash ^a   Mehta, Vimal ^b   Kalra, Ankur ^c   Sukhija, Rishi ^d   Palaniswamy, Chandrasekar ^d  

^a GRIFFIN HOSPITAL   (United States)

^b G B PANT HOSPITAL   (India)

^c Division of Female Pelvic Medicine and Reconstructive Surgery   (United States)

^d WESTCHESTER MEDICAL CENTER   (United States)

Author keywords

antithrombotic agents; protease activated receptor; Thrombin

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ATOPAXAR; HEPARIN; PROTEINASE ACTIVATED RECEPTOR 1; THROMBIN RECEPTOR ANTAGONIST; TICLOPIDINE; VORAPAXAR;

ANTICOAGULANT THERAPY; BLEEDING; BLOOD CLOT LYSIS; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; DEATH; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; HEALTH CARE QUALITY; HEART CATHETERIZATION; HEART DISEASE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; LOADING DRUG DOSE; LONG TERM CARE; MAINTENANCE DRUG DOSE; MAINTENANCE THERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; VASODILATATION;

CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG DESIGN; HEMORRHAGE; HUMANS; LACTONES; PLATELET AGGREGATION INHIBITORS; PYRIDINES; RECEPTOR, PAR-1; RECEPTORS, THROMBIN;

EID: 84870243949     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181ff7c16     Document Type: Review

References (38)

1. Jennings LK. Role of platelets in atherothrombosis. Am J Cardiol. 2009;103:A4-A10.
2. Fox KA, Anderson FA, Jr, Goodman SG, et al. Time course of events in acute coronary syndromes: implications for clinical practice from the GRACE registry. Nat Clin Pract Cardiovasc Med. 2008;5:580-589.
3. Antman EM,Wiviott SD, Murphy SA, et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel- Thrombolysis in Myocardial Infarction) analysis. J Am Coll Cardiol. 2008;51:2028-2033. (Pubitemid 351689056)
4. Sugunaraj JP, Palaniswamy C, Selvaraj DR, et al. Clopidogrel resistance. Am J Ther. 2010;17:210-215.
5. Gailani D, Renne T. Intrinsic pathway of coagulation and arterial thrombosis. Arterioscler Thromb Vasc Biol. 2007;27: 2507-2513. (Pubitemid 350158899)
6. LegerAJ, Covic L, KuliopulosA. Protease-activated receptors in cardiovascular diseases. Circulation. 2006;114:1070-1077. (Pubitemid 44358884)
7. Hirano K, KanaideH. Role of protease-activated receptors in the vascular system. J Atheroscler Thromb. 2003;10:211-225.
8. Ossovskaya VS, Bunnett NW. Protease-activated receptors: contribution to physiology and disease. Physiol Rev. 2004;84:579-621. (Pubitemid 38365493)
9. Martorell L, Martinez-Gonzalez J, Rodriguez C, et al. Thrombin and protease-activated receptors (PARs) in atherothrombosis. Thromb Haemost. 2008;99:305-315. (Pubitemid 351230960)
10. Rabiet MJ, Plantier JL, Dejana E. Thrombin-induced endothelial cell dysfunction. Br Med Bull. 1994;50:936-945. (Pubitemid 24360976)
11. McNamara CA, Sarembock IJ, Gimple LW, et al. Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor. J Clin Invest. 1993;91:94-98. (Pubitemid 23037258)
12. Gudmundsdottir IJ, Lang NN, Boon NA, et al. Role of the endothelium in the vascular effects of the thrombin receptor (protease-activated receptor type 1) in humans. J Am Coll Cardiol. 2008;51:1749-1756. (Pubitemid 351621987)
13. Ku DD, Zaleski JK. Receptor mechanism of thrombin-induced endothelium-dependent and endothelium-independent coronary vascular effects in dogs. J Cardiovasc Pharmacol. 1993;22: 609-616. (Pubitemid 23286758)
14. Rabiet MJ, Plantier JL, Rival Y, et al. Thrombin-induced increase in endothelial permeability is associated with changes in cell-to-cell junction organization. Arterioscler Thromb Vasc Biol. 1996;16:488-496. (Pubitemid 26084325)
15. Maragoudakis ME, Kraniti N, Giannopoulou E, et al. Modulation of angiogenesis and progelatinase a by thrombin receptor mimetics and antagonists. Endothelium. 2001;8:195-205. (Pubitemid 34056069)
16. Takada M, Tanaka H, Yamada T, et al. Antibody to thrombin receptor inhibits neointimal smooth muscle cell accumulation without causing inhibition of platelet aggregation or altering hemostatic parameters after angioplasty in rat. Circ Res. 1998;82:980-987. (Pubitemid 28225938)
17. Nadal-Wollbold F, Bocquet A, Bourbon T, et al. Proteaseactivated receptor 1 antagonists prevent platelet aggregation and adhesion without affecting thrombin time. Eur J Pharmacol. 2010;644:188-194.
18. Chackalamannil S, Davies RJ, Wang Y, et al. Total Synthesis of (+)-Himbacine and (+)-Himbeline. J Org Chem. 1999;64:1932-1940. (Pubitemid 29152740)
19. Becker RC, Moliterno DJ, Jennings LK, et al. Safety and tolerability of SCH 530348 in patients undergoing nonurgent percutaneous coronary intervention: a randomised, double-blind, placebo controlled phase II study. Lancet. 2009;373:919-928.
20. Kosoglou T, Reyderman L, Kasserra C, et al. Optimizing dose of the novel thrombin receptor antagonist SCH530348 based on pharmacodynamics and pharmacokinetics in healthy subjects. Clin Pharmacol Ther. 2008;83(Suppl 1):S55.
21. YusufS,ZhaoF,MehtaSR,etal.Effectsofclopidogrel inaddition to aspirin in patients with acute coronary syndromes without ST-segment elevation.NEngl JMed. 2001;345:494-502. (Pubitemid 32758501)
22. Steinhubl SR, Berger PB, Mann JT, 3rd, et al. Clopidogrel for the reduction of events during observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411-2420. (Pubitemid 35340537)
23. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-2015. (Pubitemid 350106708)
24. Eikelboom JW, Weitz JI, Budaj A, et al. Clopidogrel does not suppress blood markers of coagulation activation in aspirin-treated patients with non-ST-elevation acute coronary syndromes. Eur Heart J. 2002;23:1771-1779. (Pubitemid 35334270)
25. Wiviott SD, Antman EM, Winters KJ, et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation. 2005; 111:3366-3373. (Pubitemid 40931949)
26. Goto S, Yamaguchi T, Ikeda Y, et al. Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome. J Atheroscler Thromb. 2010;17:156-164.
27. Shinohara Y, Goto S, Shimizu K, et al. A phase II safety study of novel antiplatelet agent, SCH530348, in japanese ptients with prior ischaemic stroke. Int J Stroke. 2008(Suppl 3):139.
28. TRA*CER Executive and Steering Committees. The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale. Am Heart J. 2009;158: 327-334.e4.
29. Morrow DA, Scirica BM, Fox KA, et al. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. Am Heart J. 2009;158:335-341.e3.
30. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.
31. Gudmundsdottir IJ,Megson IL, Kell JS, et al. Direct vascular effects of protease-activated receptor type 1 agonism in vivo in humans. Circulation. 2006;114:1625-1632. (Pubitemid 44547433)
32. Lang NN, Guethmundsdottir IJ, Newby DE. Vascular PAR-1: activity and antagonism [published online ahead of print May 27, 2010]. Cardiovasc Ther. doi: 10.1111/j.1755-5922.2010.00140.x.
33. Ueno M, Ferreiro JL, Angiolillo DJ. Mechanism of action and clinical development of platelet thrombin receptor antagonists. Expert Rev Cardiovasc Ther. 2010;8:1191-1200.
34. Goto S, Ogawa H, Takeuchi M, et al. Double-blind, placebo-controlled Phase II studies of the proteaseactivated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or highrisk coronary artery disease. Eur Heart J. 2010;31:2601-2613.
35. Leonardi S, Tricoci P, Becker RC. Thrombin receptor antagonists for the treatment of atherothrombosis: therapeutic potential of vorapaxar and e-5555. Drugs. 2010;70:1771-1783.
36. Lopez-Pedrera C, Aguirre MA, Buendia P, et al. Differential expression of protease-activated receptors in monocytes from patients with primary antiphospholipid syndrome. Arthritis Rheum.2010;62:869-877.
37. Maki J, Hirano M, Hoka S, et al. Thrombin activation of proteinase-activated receptor 1 potentiates the myofilament Ca2+ sensitivity and induces vasoconstriction in porcine pulmonary arteries. Br J Pharmacol. 2010;159: 919-927.
38. Mihara M, Aihara K, Ikeda Y, et al. Inhibition of thrombin action ameliorates insulin resistance in type 2 diabetic db/db mice. Endocrinology. 2010;151:513-519.